Dogwood Therapeutics Files New Synthetic Halneuron(R) Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045
Dogwood Therapeutics (Nasdaq: DWTX) filed a new composition of matter intellectual property application for a fully synthetically manufactured Halneuron® on December 2, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Dogwood Therapeutics (Nasdaq: DWTX) filed a new composition of matter intellectual property application for a fully synthetically manufactured Halneuron® on December 2, 2025. The company says the synthetic process delivers higher manufacturing yields and lower costs versus naturally harvested Halneuron® and is planned for use in Phase 3 development and commercialization. If the IP is granted, Dogwood projects the exclusivity period could extend to 2045, before any additional patent term restoration.
Positive
- Filed composition-of-matter IP for synthetic Halneuron
- Synthetic process claims higher manufacturing yields
- Synthetic process claims reduced manufacturing costs
- Company plans to use synthetic Halneuron in Phase 3 and commercialization
- Projected exclusivity extension to 2045 if IP granted
Negative
- Exclusivity extension is contingent on IP grant, not guaranteed
Details
News Market Reaction – DWTX
On Dec 2, the day this news came out, DWTX closed 2.05% below the previous close.
Data tracked by StockTitan Argus for the Dec 2 session.
Key Figures
- Projected exclusivity
- to 2045
- If new synthetic Halneuron® IP is granted
- Planned Phase 2b size
- 200 patients
- HALT-CINP Phase 2b trial target enrollment
- Patients enrolled
- 100 patients
- First 100 patients enrolled in Halneuron® Phase 2b
- Q3 2025 net loss
- $15.7M
- Quarter ended September 30, 2025
- Cash balance
- $10.1M
- Q3 2025 cash, runway through Q1 2026
- Registered resale shares
- 28,038,689 shares
- Shares registered under Form S-3/A for selling stockholders
- Shares outstanding
- 2,293,162 shares
- Common shares outstanding as of October 16, 2025
- Price vs 52-week high
- -78.07%
- Versus 52-week high of $29.28 before this news
Historical Context
-
Filed new composition-of-matter IP for synthetic Halneuron® to extend exclusivity.
-
Reported first 100 patients enrolled in Halneuron® Phase 2b, interim analysis on track.
-
Disclosed higher R&D, $15.7M net loss and going-concern uncertainty beyond Q1 2026.
-
Announced timing of Q3 2025 financial results release before market open.
-
Flagged CEO participation and investor meetings at Maxim Growth Summit 2025.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
composition of matter regulatory
intellectual property regulatory
phase 3 medical
exclusivity period regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
- New Composition of Matter Intellectual Property ("IP") Filing Centered on First-in-Class, Fully Synthetically Manufactured Halneuron®-
- New Synthetic Process to be Used for Phase 3 Development Provides Higher Manufacturing Yields and Reduces Costs Versus Naturally Harvested Halneuron® -
ATLANTA, GA / ACCESS Newswire / December 2, 2025 / Dogwood Therapeutics, Inc. (Nasdaq:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced it has filed for new intellectual property protection for synthetic Halneuron®. If granted, the IP's exclusivity period will extend to 2045, before additional patent term restoration extensions.
"We plan to use synthetically manufactured Halneuron® in both Phase 3 development and commercialization," said Greg Duncan, Dogwood Therapeutics Chief Executive Officer. "This new synthetic process builds on our proprietary and best-in-class manufacturing know-how, with potential to reset our exclusivity period for 20 years, thus providing ample opportunity to deliver Halneuron's® full commercial potential."
About Halneuron®
Our lead product candidate, Halneuron®, is in Phase 2b development as a non-opioid, NaV 1.7 inhibitor to treat pain conditions including the neuropathic pain associated with chemotherapy treatment ("CINP"). Halneuron® has been granted fast track designation from the Food and Drug Administration ("FDA") for the treatment of CINP. Success in this Phase 2b study will serve as the basis for the Company engaging the FDA to align on the Halneuron® Phase 3 development program requirements.
About Dogwood Therapeutics
Dogwood Therapeutics (Nasdaq:DWTX) is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathic disorders. The Dogwood research pipeline includes two first-in-class development candidates, Halneuron® and SP16 IV.
Our lead product candidate, Halneuron®, is in Phase 2b development to treat pain conditions including the neuropathic pain associated with chemotherapy treatment. Halneuron® has been granted fast track designation from the FDA for the treatment of CINP. Halneuron® is a non-opioid, NaV 1.7 analgesic which is a highly specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron® treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain ("CINP").
SP16 IV is a low-density lipoprotein receptor related protein-1 (LRP1) agonist with potential to treat neuropathy and prevent or repair nerve damage following chemotherapy. SP16 acts as an LRP1 agonist that in turn provides alpha-1-antitrypsin-like activity. Consistent with alpha-1-antitrypsin anti-inflammatory and immunomodulatory actions, SP16 preclinically demonstrated anti-inflammatory (analgesic) action via potential reductions in IL-6, IL-8, IL1B and TNF-alpha levels, as well as potential to repair damaged tissue via increases in pAKT and pERK that regulate fundamental processes like growth, proliferation and survival. The forthcoming SP16 IV Phase 1b CINP trial is fully funded by the National Cancer Institute.
For more information, please visit www.dwtx.com.
Forward-Looking Statements:
Statements in this press release contain "forward-looking statements," within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "suggest," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Dogwood's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion, timing and results of current and future clinical studies relating to Dogwood's product candidates. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in the Annual Report on Form 10-K for the year ended December 31, 2024, which has been filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Dogwood undertakes no duty to update such information except as required under applicable law.
Investor Relations:
CORE IR
(516) 222-2560
IR@dwtx.com
SOURCE: Dogwood Therapeutics, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.